PT-141 (Bremelanotide) 10 mg
PT-141 (Bremelanotide) · 10mg
A melanocortin-receptor agonist researched in sexual desire and arousal.
- Research focus: melanocortin signalling, sexual desire and arousal
- Evidence: substantial human clinical-trial evidence exists for prescription bremelanotide
- Format: research vial
What is PT-141?
PT-141 is the research name commonly used for bremelanotide, a melanocortin receptor agonist.
What has it been studied for?
Large randomised Phase 3 trials studied bremelanotide in premenopausal women with hypoactive sexual desire disorder and found improvements in desire and related distress compared with placebo.
Is there an approved medicine related to PT-141?
Yes. Bremelanotide is the active ingredient in the US prescription medicine Vyleesi. A research-grade PT-141 product is not the same regulated medicine.
Research links
Research-use restriction
For laboratory research use only. Not for human or veterinary use, consumption, diagnosis, treatment or administration. Availability remains unconfirmed until the specific supplier, stock and batch documentation are verified.